Propranolol (English name: propranolol , Chinese trade name: 心得安) is a first-line drug for the treatment of hemangioma in infants and children, and its effectiveness and safety have been proven. The drug has mild side effects and can be used safely on its own. The first report was published in the New England Journal of Medicine (NEJM) in June 2008, and was also presented at the International Society for the Study of Vascular and Angiomatous Diseases (ISSVA) Congress in Boston, making it one of the most significant discoveries in the history of hemangioma treatment. It is one of the most significant discoveries in the history of hemangioma treatment. Pre-dose physical examination: electrocardiogram, cardiac ultrasound, routine blood tests. Exclude arrhythmia, severe conduction block, congenital heart disease and other disorders; exclude bronchitis, pneumonia, asthma. Contraindications: Propranolol, a traditional drug that has been used for decades, is indicated with contraindications including cardiac lesions (conduction block), airway sensitivity disorders, ventilation difficulties, or other pulmonary disorders. Drug Specification: 100 tablets/bottle, 10mg/tablet. Dosing method: Day 1: 0.5mg/kg body weight per dose, once in the morning and once in the evening at 8:00 a.m. Day 2: 0.75mg/kg body weight per dose, once in the morning and once in the evening at 8:00 a.m. Day 3: 1.0mg/kg body weight per dose, once in the morning and once in the evening at 8:00 a.m. Day 3: 1.0mg/kg body weight per dose, once in the morning and once in the evening at 8:00 a.m. Day 4: 1.0mg/kg body weight per dose, once in the morning and once in the evening at 8:00 a.m. (e.g., if the child weighs 5 kg, on the first day, take 2.5 mg, i.e., 1/4 tablet, once in the morning and once in the evening at 8:00 a.m.); on the second day, take 3.75 mg, measured precisely with a syringe, once in the morning and once in the evening at 8:00 a.m.; on the third day, take 5 mg, i.e., half tablet, once in the morning and once in the evening. Note to parents: Take the weight once a week and set the dosage for the week. The tablets can be ground into a powder or dissolved in water or milk (formula) for precise dosage. Take the tablet half an hour after eating (do not take it on an empty stomach) to avoid hypoglycemia. If the child has vomiting and other conditions, do not arbitrarily increase the amount of medicine, rather less than more. The normal vaccination will not be affected by the use of Takayasu, and the vaccination can be carried out normally 4 hours after taking the medicine. Diarrhea, hypotension, bradycardia, hypoglycemia, tracheospasm and other complications may occur after taking the drug. During the whole course of treatment, the child’s breathing, heart rate (measure the heart rate half an hour after taking the medicine and record it), mental status, diet, whether there is milk spillage, sleep, urine and stool, skin rash, especially the respiratory condition, should be closely observed. In case of severe diarrhea, the drug should be stopped and taken again after adaptation. Hypotension, bradycardia and hypoglycemia generally have no subjective symptoms and do not require treatment. Other special cases need to be reviewed at any time. Children taking the drug for the first time are recommended to be hospitalized on the first day, while monitoring their vital signs. After 1 month of taking the drug, the child should register for a follow-up consultation on Wednesday or Friday afternoon at the hemangioma clinic, and the doctor will judge the effect of treatment and formulate a follow-up treatment plan. Adverse effects: Common adverse effects include hypoglycemia, hypotension, slowed heart rate, diarrhea, sleep changes, asthma attacks, while others such as chills in the hands and feet, irritability, sweating, constipation, convulsions, lethargy, hypothermia, etc. are rare. They usually occur at the beginning of treatment and most of them do not require special treatment or only symptomatic treatment and can recover after a few days without affecting the continuation of treatment. There was no significant difference in blood glucose, liver and kidney function and thyroid function before and after treatment. The efficacy of propranolol on proliferative hemangiomas in infants and children was significantly better than that of glucocorticoids. From the current clinical treatment effect, together with the detailed evaluation and analysis of safety and side effects established over 40 years of propranolol use in the treatment of cardiovascular diseases in infants and children, propranolol is a safer and more convenient drug for the treatment of hemangiomas in infants and children.